TY - JOUR T1 - Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort JF - Gut JO - Gut SP - 2013 LP - 2015 DO - 10.1136/gutjnl-2020-323672 VL - 70 IS - 10 AU - Seung Won Lee AU - Jee Myung Yang AU - In Kyung Yoo AU - Sung Yong Moon AU - Eun Kyo Ha AU - Abdullah Özgür Yeniova AU - Joo Young Cho AU - Min Seo Kim AU - Jae Il Shin AU - Dong Keon Yon Y1 - 2021/10/01 UR - http://gut.bmj.com/content/70/10/2013.abstract N2 - We appreciate the comment and discussion from Dr Roulet1 on our original article.2 The author criticised that (1) our study did not consider the dose-dependent exposure to proton pump inhibitors (PPIs); (2) our study did not investigate the relationship of PPI use in hospitalised patients with COVID-19 during treatment for COVID-19 and (3) although our study accounted for protopathic bias by excluding new non-steroidal anti-inflammatory drug users, protopathic bias occurred in patients who responded to the early digestive symptoms of COVID-19. We acknowledge that plausible academic concerns have been raised, which might improve the original discussion and extend the insight into the association between PPI usage and COVID-19.1 We have performed a post-hoc analysis from the Korean nationwide cohort, addressing these concern.Data were obtained from the Korean nationwide cohort study, which includes patients (≥18 years) who underwent SARS-CoV-2 testing between 1 January and 15 May 2020.2–4 We performed propensity score matching between current PPI users (prehospitalisation PPI usage) and non-users among patients with laboratory-confirmed COVID-19 (n=4785), as previously described.2 Posthospitalisation PPI usage was defined as in-hospital PPI use in general wards, not intensive care units. The outcomes were a composite endpoint 1 (requirement of oxygen therapy, intensive care unit admission, administration of invasive ventilation or death) and a composite endpoint … ER -